Full-Time

Clinical Research Coordinator

Deadline 7/22/25
Insulet Corporation

Insulet Corporation

1,001-5,000 employees

Develops insulin delivery systems for diabetes

Compensation Overview

$34 - $51.25/hr

Acton, MA, USA

Hybrid

Requires on-site work from an Insulet office at least 3x/week.

Category
🧬Biology & Biotech (1)
Requirements
  • Associates degree/or an equivalent combination of education or experience
  • Minimum of 2-4 years of experience in a clinical setting
  • Direct experience in participating in the execution of clinical research studies
  • Must have analytical skill, be detail oriented and have good interpersonal skills
  • Knowledge of agency guidelines and requirements
Responsibilities
  • Review and prepare clinical study budgets for finalization
  • Collect study metrics to disseminate to the internal teams
  • Assists with the update and maintenance of clinical schedules, trackers, and documentation
  • Support the management of clinical document version control and upload to document control platform
  • Maintain studies on clinicaltrials.gov
  • Prepare distribution of copies of finalized study documentation
  • Maintain and organize clinical directories
  • Maintain electronic Trial Master File (eTMF)
  • Requests POs and tracks all study related invoices
  • Participates in team meetings and tracks action items
  • Performs other duties as required
Desired Qualifications
  • Excellent written and effective verbal communication skills
  • Project management skills
  • Ability to communicate cross-functionally across the organization
  • PC skills; word processing, spreadsheet, database, Internet search and utilization
  • Flexible and able to work in a fast paced environment
  • Team player
  • Ability to organize and judge priorities
  • Excellent ability to generate and maintain accurate records

Insulet Corporation develops and manufactures insulin delivery systems specifically for individuals with diabetes. Its main product, the Omnipod, is a tubeless and waterproof insulin pump that allows for continuous insulin infusion under the skin. This system is designed to be more convenient and discreet compared to traditional insulin pumps that use tubing, making diabetes management easier for users. Insulet operates globally, with its headquarters in Acton, Massachusetts, and various manufacturing facilities around the world. The company focuses on selling the Omnipod system, which includes disposable pods and a personal diabetes manager (PDM). Insulet targets people with insulin-dependent diabetes who prefer a flexible and user-friendly method of insulin delivery. The company is also advancing its product offerings, such as the Omnipod 5, which features automated insulin delivery that works with continuous glucose monitors.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Omnipod 5 iPhone app launch enhances user experience with Dexcom G7 compatibility.
  • Insulet's humorous campaign and Marvel collaboration boost brand visibility and engagement.
  • $450M raised through senior notes optimizes capital structure for future growth.

What critics are saying

  • CEO transition may lead to strategic shifts or instability during the transition period.
  • Increased competition from Tandem Diabetes Care could impact Insulet's market share.
  • Integration of Omnipod 5 with Dexcom G7 may face technical challenges or user adoption issues.

What makes Insulet Corporation unique

  • Omnipod is tubeless and waterproof, unlike traditional insulin pumps with tubing.
  • Omnipod 5 integrates with CGMs, offering automated insulin delivery for personalized diabetes management.
  • Insulet's global presence and innovative product line set it apart in diabetes care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Diabetic Investor
Jun 25th, 2025
ADA 2025 - Winners and losers

It goes without saying that Insulet was not just the winner of ADA 2025 it won by a landslide.

TTF Valve
Jun 12th, 2025
Insulet (NasdaqGS:PODD) Launches Omnipod 5 iPhone App With Dexcom G7 Compatibility - Simply Wall St News

Insulet (NasdaqGS:PODD) launches Omnipod 5 iPhone App with Dexcom G7 compatibility - Simply Wall St news.

MediaPost
Jun 11th, 2025
Insulet Boosts Its Diabetes Device Via Comical Campaign - And A Comic Book

Insulet has launched a humorous paid social campaign for its wearable Omnipod 5 insulin delivery system - and teamed with Marvel for a stigma-busting comic book starring a teen heroine with diabetes.

RTTNews
Apr 28th, 2025
Insulet CEO Jim Hollingshead Resigns, Ashley McEvoy To Succeed; Raises Q1 Guidance

Insulet Corp. (PODD), a medical device company, on Monday announced that Chief Executive Officer Jim Hollingshead has resigned from the Board of Directors.

MD+DI
Apr 28th, 2025
Insulet Names Ex-J&J MedTech Chief Ashley McEvoy as CEO

Ashley McEvoy has been tapped to be president and CEO of Insulet.